China Animal Healthcare (EP4.SG) down 1.5% at $0.33 in light trade, pausing for breather after last week's 8.1% gain, 19.6% rally since start of September, says Dow Jones.

Recent run-up driven partly by hopes for better valuations as animal-vaccine maker seeks dual listing in HK. Stock may have room to head higher if company successful in China government tender exercise next month for supply of hand, foot and mouth disease vaccine.

"(Looking) at the share price and volume surge in the last 1 week, and off-the-cuff chat with traders in the market, we suspect that there is some serious accumulation in the market," says CIMB analyst Gary Ng; adds "we will not be surprised if other institutional names jump into the fray."

Private equity group Blackstone invested almost US$50 million ($66.1 million) in company in July. Support for time being tipped at 15-day moving average, last at $0.31.